A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Active Eosinophilic Esophagitis
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Cendakimab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 26 Aug 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 08 Aug 2023 Planned primary completion date changed from 5 Dec 2023 to 27 Dec 2023.
- 08 Aug 2023 Status changed from recruiting to active, no longer recruiting.